Bryan Garnier - Media Analytics Corp (MEDA) MEDARTIS BUY | CHF60 vs. CHF57 Leaving the Joint for the Extremity

Report

Bryan Garnier

Victor Floc’h

MEDARTIS BUY | CHF60 vs. CHF57 Leaving the Joint for the Extremity

1H20 offers solid foundation for things to come
Medartis hits the right notes in regards to US
Investors should elect Trauma over Elective surgery exposure
Update post 1H20, FV to CHF60 vs CHF57, re-iterate Buy

20/08/2020 5 EN

Underlying

Media Analytics Corp

See profile

US5843932014 Pink OTC Markets United States

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Victor Floc’h

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Bryan Garnier

MEDARTIS: Remove Medartis from top picks after strong performance | BUY | CHF80(-11%)

MEDARTIS - BUY | CHF80(-11%) Remove Medartis from top picks after strong performance Medartis doubled YTD, and returned 28% since entering top picks Extremities still offers great growth to LT investors Largest opportunities still ahead Retain BUY TP CHF80, inorganic growth key catalyst for share

June 10, 2021 June 10, 2021 4 EN

Bryan Garnier

MEDARTIS: Reaching for the stars, in post-COVID extremities | BUY | CHF80 VS. 60(-2%)

MEDARTIS - BUY | CHF80 VS. 60(-2%) Reaching for the stars, in post-COVID extremities US strategy paying off KeriMedical allows Medartis to touch new markets More M&A on the agenda Update estimates TP EUR 80 (from EUR 60), retain BUY

March 30, 2021 March 30, 2021 3 EN

Edenred: re-accelerating in Q1 2024

Edenred has reported robust sales numbers with operating revenue re-accelerating to +16.9%, well ahead of market expectations at 14.2%. Resilient demand and the largely under-penetrated market addressed by the firm hint at a continuation in the growth trends observed today, and add weight to our or

21h / 4m 21h / 4m 1 EN

Paul Charpentier

Paul Charpentier

Planisware to start trading on 18th April with a EUR1.1bn valuation

On Tuesday, Planisware (not covered), a French B2B software publisher, announced it would float its shares on the Paris stock exchange on 18th April at a valuation of EUR1.1bn. As a reminder, the listing comes after the IPO project was called off in October 2023 due to unfavourable market condition

21h / 10m 21h / 10m 1 EN

Loic Morvan ... (+2)

Loic Morvan
Paul Rouviere

LVMH: Q1 might be the low point for F&LG growth

As anticipated, LVMH reported a quite poor Q1 2024 performance, with a 3% sales growth (at same FX), but at least in line with consensus expectations and with no dramatic trend. Furthermore, we remind investors that LVMH faced a fairly demanding comparison basis (sales were up 17% in Q1 23). We rei

April 17, 2024 April 17, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

MEDARTIS BUY | CHF60 vs. CHF57 Leaving the Joint for the Extremity

Monthly LMI Update Independent Investment Research

MEDARTIS: Remove Medartis from top picks after strong performance | BUY | CHF80(-11%)

MEDARTIS: Reaching for the stars, in post-COVID extremities | BUY | CHF80 VS. 60(-2%)

Edenred: re-accelerating in Q1 2024

Planisware to start trading on 18th April with a EUR1.1bn valuation

LVMH: Q1 might be the low point for F&LG growth

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe